San Francisco, Nov 22 The
global next
generation cancer diagnostics market is anticipated to reach USD
11.04 billion by 2024, according to a new report by Grand View Research, Inc.
Key drivers for this vertical include rising advancement in genomics and
proteomics-based research coupled with increasing prevalence of oncology
disorders.
Rise
in number of oncological research projects to elucidate tumorigenesis and the
underlying mechanisms, consequently raising the demand for serial sampling,
diagnosis, and therapeutic manipulation, is a growth rendering driver of this
market.
Browse full research report on Next Generation Cancer Diagnostics Market:
www.grandviewresearch.com/industry-analysis/next-generation-cancer-diagnostics-market
Further Key Findings from the Study Suggest:
- The qPCR
& multiplexing segment captured the largest market share in 2015 owing
to the presence of a wide product portfolio serving numerous applications
in oncology R&D
- Next
generation sequencing services and solutions for oncology applications are
anticipated to be the fastest growing segment
- Oncology
diagnostics in biomarker discovery is expected witness growth as it
subsequently facilitates drug designing and identification of novel
targets against tumors
- On the basis
of cancer type, this vertical is segmented into lung, breast, colorectal,
cervical, and other forms of cancer
- Research
projects to establish the therapeutic index of anticancer cytotoxic drugs
are one of the key factors responsible for expected growth
- North America
dominated the market with respect to revenue generation in 2014 due to
concerted efforts directed toward the development of next generation
sequencing technology and companion diagnostics in personalized medicine
- Some of the
key players contributing significantly to the next generation cancer
diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.;
PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific,
Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.;
Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.;
Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.
Browse more reports of this category
by Grand View Research: www.grandviewresearch.com/industry/biotechnology
Grand
View Research has segmented the next generation cancer diagnostics market on
the basis of technology, application, cancer type, function, and region:
Technology
Outlook (Revenue, USD Million, 2013 - 2024)
- Next
Generation Sequencing
- qPCR &
Multiplexing
- Lab-on- a-
chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
- Protein
Microarrays
- DNA
Microarrays
Application
Outlook (Revenue, USD Million, 2013 - 2024)
- Biomarker
Development
- CTC Analysis
- Proteomic
Analysis
- Epigenetic
Analysis
- Genetic
Analysis
Cancer
Type Outlook (Revenue, USD Million, 2013 - 2024)
- Lung Cancer
- Breast Cancer
- Colorectal
Cancer
- Cervical
Cancer
- Others
Function
Outlook (Revenue, USD Million, 2013 - 2024)
- Therapeutic
Monitoring
- Companion
Diagnostics
- Prognostics
- Cancer
Screening
- Risk Analysis
Regional
Outlook (Revenue, USD Million, 2013 - 2024)
- North America
- U.S
- Canada
- Europe
- Germany
- France
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Middle East
& Africa
- South Africa
Browse press release of this report
by Grand View Research: www.grandviewresearch.com/press-release/global-next-generation-cancer-diagnostics-market
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information:
www.grandviewresearch.com
No comments:
Post a Comment